Evidence map›Paper›PMID 39516331›Full record

ReviewMedical oncology (Northwood, London, England)2024

lncRNAs'p potential roles in the pathogenesis of cancer via interacting with signaling pathways; special focus on lncRNA-mediated signaling dysregulation in lung cancer.

Sulieman Ibrahim Shelash, Ibraheem Abdulnabi Shabeeb, Irfan Ahmad, Hiba Muwafaq Saleem, Pooja Bansal, Abhinav Kumar, Mahamedha Deorari, Anaheed Hussein Kareem, Ahmed Muzahem Al-Ani, Munther Kadhim Abosaoda

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medical oncology (Northwood, London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sulieman Ibrahim ShelashElectronic Marketing and Social Media, Economic and Administrative Sciences Zarqa University, Zarqa, Jordan.
Ibraheem Abdulnabi ShabeebDepartment of Biology, College of Science, University Of Anbar, Ramadi, Iraq. sc.ibrahim_77alani@uoanbar.edu.iq.
Irfan AhmadDepartment of Clinical Laboratory Sciences, College of Applied Medical Science, King Khalid University, Abha, Saudi Arabia.
Hiba Muwafaq SaleemDepartment of Biology, College of Science, University Of Anbar, Ramadi, Iraq. hiba.muwafaq@uoanbar.edu.iq.
Pooja BansalDepartment of Biotechnology and Genetics, Jain (Deemed-to-Be) University, Bengaluru, 560069, Karnataka, India.
Abhinav KumarDepartment of Nuclear and Renewable Energy, Ural Federal University Named After the First President of Russia Boris Yeltsin, Ekaterinburg, 620002, Russia.
Mahamedha DeorariUttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, India.
Anaheed Hussein KareemCollege of Health and Medical Technology, Al-Ayen University, Thi-Qar, 64001, Iraq.
Ahmed Muzahem Al-AniDepartment of Medical Engineering, Al-Nisour University College, Baghdad, Iraq.
Munther Kadhim AbosaodaCollege of Pharmacy, The Islamic University, Najaf, Iraq.

Funding

Deanship of Scientific Research, King Khalid University R.G.P.1/323/44
6 · The paper itself

Abstract

Lung cancer ranks among the most lethal types of cancer globally, with a high occurrence and fatality rate. The spread of cancer to other parts of the body, known as metastasis, is the primary cause of treatment failure and death in lung cancer cases. Current approaches for treating advanced lung cancer typically involve a combination of chemotherapy and targeted therapy. However, the majority of patients ultimately develop resistance to these treatments, leading to a worsened prognosis. In recent years, cancer biology research has predominantly focused on the role of protein-encoding genes in cancer development. Long non-coding RNAs (lncRNAs) are transcripts over 200 nucleotides in length that do not encode proteins but are crucial RNA molecules involved in numerous biological functions. While many functions of lncRNAs remain unknown, some have been linked to human diseases, including cancer. Studies have demonstrated that lncRNAs interact with other large molecules in the cell, such as proteins, DNA, and RNA, influencing various critical aspects of cancer. LncRNAs play a significant role in regulating gene expression and have a crucial function in the transcriptional regulation of cancer cells. They mediate various biological and clinical processes such as invasion, metastasis, apoptosis, and cell proliferation. Dysregulation of lncRNAs has been found to impact the process of carcinogenesis through advanced technologies like RNA sequencing and microarrays. Collectively, these long non-coding RNAs hold promise as potential biomarkers and therapeutic targets for human cancers. In this segment, we provide a comprehensive summary of the literature on the characteristics and formation of lncRNAs, along with an overview of their current known roles in lung cancer.

Indexed as

Gene Expression Regulation, NeoplasticLung NeoplasmsRNA, Long NoncodingSignal TransductionHumansRNA, Long NoncodingCancerlncRNAsLung cancerSignaling pathways

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.